Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
A phase 2 trial of durvalumab, gemcitabine, cisplatin and nab-paclitaxel in gallbladder cancer, run by Fudan University, now recruiting.
Overview
Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer is a phase 2 interventional study registered as NCT06591650 by Fudan University, with a registry enrolment figure of 33 participants, started 2024-10-24 and due to reach its primary completion in 2026-10-30. Interventions recorded: gemcitabine hydrochloride, Cisplatin, Nab-paclitaxel, Durvalumab. Conditions listed: Gallbladder Cancer Unresectable. Sites: China. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialDurvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents and the tag gallbladder-deep-dive.
- TrialCTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialThe Purpose of This Research Study is to See if Combining Gemcitabine, Cisplatin and Durvalumab Chemotherapy Treatments With a Direct Tumor Therapy Yittrium-90 (Y-90) Will Work Better Together to Shrink Tumors and Control Cancer
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialMP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialAK112 Combined With GAP Conversion Therapy for Locally Advanced Gallbladder Cancer
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.
- TrialGemcitabine and Nab-Paclitaxel Combined With Iparomlimab and Tuvorilimab for Advanced Gallbladder Cancer
Shares Nab-paclitaxel, Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Gemcitabine, Gallbladder cancer and the tag gallbladder-deep-dive.
- TrialDurvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)
Shares Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Durvalumab, Platinum agents, Gemcitabine and the tag gallbladder-deep-dive.